Author:
Lazzeroni Matteo,Serrano Davide,Dunn Barbara K,Heckman-Stoddard Brandy M,Lee Oukseub,Khan Seema,Decensi Andrea
Publisher
Springer Science and Business Media LLC
Reference80 articles.
1. Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD: Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol. 2006, 24: 1332-1341.
2. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005, 97: 1652-1662. 10.1093/jnci/dji372.
3. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998, 351: 1451-1467.
4. Maltoni C, Minardi F, Belpoggi F, Pinto C, Lenzi A, Filippini F: Experimental results on the chemopreventive and side effects of tamoxifen using a human-equivalent animal model. The Scientific Bases of Cancer Chemoprevention. Edited by: Maltoni C, Soffritti M, Davis W. 1996, Elsevier Science BV, 197-207.
5. Coezy E, Borgna JL, Rochefort H: Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 1982, 42: 317-323.
Cited by
65 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献